Physician profile
Mark Dewayne Murray
NPI 1205896214
$5,277.35
in general payments reported to CMS, 2019-2025
22 companies · $870 in 2025
The $870 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $446 · 2021: $543 · 2022: $613 · 2023: $1,162 · 2024: $1,374 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,385 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,385.00 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,475.08 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $754.99 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $522.96 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $477.31 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $187.19 | 2023-2025 | |
| Lilly USA, LLC | $139.39 | 2023-2024 | Omvoh |
| Boston Scientific Corporation | $111.28 | 2019-2020 | |
| Janssen Biotech, INC. | $105.15 | 2023-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $80.68 | 2023 | Dupixent |
| Medtronic, INC. | $77.49 | 2024 | Gi Genius |
| Ironwood Pharmaceuticals, INC | $58.84 | 2020-2023 | Linzess |
| Evoke Pharma, INC. | $50.25 | 2022 | |
| Celltrion USA INC. | $43.97 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $37.79 | 2024 | Voquezna |
| Ethicon US, LLC | $34.96 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $34.69 | 2023 | Idacio |
| Braintree Laboratories, INC. | $29.40 | 2020-2021 | |
| Shionogi INC | $24.04 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.04 | 2023 | Cimzia |
| Merck Sharp & Dohme LLC | $11.91 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $3.94 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$20,735.01 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.